Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Apatinib with Chemotherapy in ES-SCLC
NCT04683198Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Apr 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib in small cell lung cancer (SCLC), sponsored by Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
camrelizumabRivoceranib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04683198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04683198.